Home › Mantle Cell Lymphoma › California
Mantle Cell Lymphoma clinical trials in California
31 studies for Mantle Cell Lymphoma are looking for participants at sites in California.
Cities in California
- Baldwin Park17 studies
- Los Angeles7 studies
- Mountain View7 studies
- San Diego5 studies
- San Francisco4 studies
- Irvine3 studies
Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy
- City of Hope Comprehensive Cancer Center, Duarte
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07003295BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL
- City of Hope Medical Center, Duarte
- Stanford University, Stanford
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT05370430A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- City of Hope, Duarte
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07101328Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
- Tower Cancer Research Foundation, Beverly Hills
- Cedars-Sinai Medical Center, Los Angeles
RecruitingPhase 3
Ages 60 and older · All sexes · Updated Nov 3, 2026 · NCT05976763Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
- City of Hope Medical Center, Duarte
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT06054776A Study of ARC-02 in B-cell NHL
- Start Cala, Los Angeles
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT07691606A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
- Ucsf Fresno, Fresno
- Kaiser Permanente Southern California, Irvine
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 29, 2026 · NCT06742996Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma
- City of Hope Medical Center, Duarte
RecruitingPhase 1/2
Ages 18 to 80 · All sexes · Updated Oct 26, 2026 · NCT05861050Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- City of Hope, Duarte
- Valkyrie Clinical Trials, Los Angeles
RecruitingPhase 1/2
Ages 13 to 90 · All sexes · Updated Oct 26, 2026 · NCT06533579Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
- University of California, San Francisco, San Francisco
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT04545762Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma
- City of Hope Medical Center, Duarte
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 22, 2026 · NCT07578077A Study of APG-3288 in Relapsed/Refractory Blood Cancers
- START Los Angele, Los Angeles
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 15, 2026 · NCT07424833Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma
- City of Hope Medical Center, Duarte
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 14, 2026 · NCT06675123Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- City of Hope Medical center, Duarte
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 14, 2026 · NCT03523975A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- University of California San Diego (Ucsd) Moores Cancer Center, La Jolla
- Stanford Medicine, Palo Alto
- UCLA Santa Monica Cancer Care, Santa Monica
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT05006716Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
- University of California, Davis, Davis
- University of California, Los Angeles, Los Angeles
- University of California, San Diego, San Diego
- and 1 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06252675A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
- Research Site, La Jolla
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT06542250Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL
- Stanford Cancer Center, Stanford
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT06553872AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
- Stanford University, Palo Alto
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 12, 2026 · NCT06340737Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
- Cedars-Sinai Medical Center, Los Angeles
RecruitingPhase 1
Ages 18 to 85 · All sexes · Updated Aug 10, 2026 · NCT05887167This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
- City of Hope, Duarte
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 24, 2026 · NCT07121946DALY II USA/ MB-CART2019.1 for DLBCL
- UC San Diego Health, La Jolla
- Stanford University, Stanford
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 13, 2026 · NCT04792489A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- City of Hope, Duarte
- University of California, San Francisco, San Francisco
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 2, 2026 · NCT05131022Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- City of Hope Medical Center, Duarte
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 20, 2026 · NCT06859008The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- City of Hope, Duarte
- Los Angeles Cancer Network, Los Angeles
- UCLA Medical Center of Hematology/Oncology, Los Angeles
- and 1 more
RecruitingPhase 1/2
Ages 12 to 95 · All sexes · Updated Apr 15, 2026 · NCT04329728A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- City of Hope, Duarte
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Mar 20, 2026 · NCT04830137Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma
- City of Hope Medical Center, Duarte
- City of Hope at Irvine Lennar, Irvine
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Mar 13, 2026 · NCT06572618Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma
- City of Hope Medical Center, Duarte
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 23, 2026 · NCT05432635AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- UC Irvine Health, Orange
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Dec 10, 2025 · NCT05602363SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Duarte
- Massive Bio SYNERGY-AI site, Irvine
- Massive Bio SYNERGY-AI site, La Jolla
- and 3 more
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy
- Stanford Cancer Center, Palo Alto
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 22, 2024 · NCT05255354From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.